Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06440005
Other study ID # AGX101-001
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 2024
Est. completion date May 2027

Study information

Verified date May 2024
Source Angiex, Inc.
Contact Paul Jaminet, PhD
Phone 617-576-1753
Email clinical@angiex.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal. Subjects will attend an end of treatment visit and will receive two safety follow-up telephone contacts up to 90 days following the last dose of study drug.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date May 2027
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed unresectable, locally advanced, or metastatic solid tumors including triple-negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC). - Refractory to or relapsed after all standard therapies known to provide proven clinical benefit, unless the patient is not a candidate for standard treatment, there is no standard treatment, or the patient refuses standard treatment after expressing an understanding of all available therapies with proven clinical benefit - Willing to authorize use of existing archival tissue, unless otherwise discussed with Sponsor - Time since the last dose of prior therapy to treat underlying malignancy (including other investigational therapy): Systemic cytotoxic chemotherapy: = the duration of the most recent cycle of the previous regimen (with a minimum of 2 weeks for all, except 6 weeks for systemic nitrosourea or systemic mitomycin-C); Biologic therapy (eg, antibodies): = 3 weeks; Small molecule therapies: = 5 × half-life - Have an ECOG performance status of 0 to 1 - Have adequate organ function - LVEF = 50%, as determined on cardiac ECHO or cardiac multiple-gated acquisition (MUGA) scan - Highly effective contraception for both male and female patients throughout the study Exclusion Criteria: - Colorectal cancer and non-small-cell lung cancer with predominant squamous histology (ie, squamous cell carcinoma of the lung) are excluded unless otherwise discussed and approved by Sponsor - Clinically unstable central nervous system (CNS) tumors or brain metastasis (stable and/or asymptomatic CNS metastases allowed) - Have not recovered to = Grade 1 or baseline from all AEs due to previous therapies (patients with = Grade 2 neuropathy, endocrine-related irAEs, or other AEs may be eligible after discussion with the Sponsor) - Has an active vasculitis that has required systemic treatment in the past 2 years prior to starting study treatment - Significant (ie, = Grade 2) ocular disturbances - Variceal bleeding within 6 months prior to treatment, currently untreated or incompletely treated varices with bleeding, or who otherwise are at a high risk of bleeding - Any other concurrent antineoplastic treatment except for allowed local radiation of lesions for palliation (to be considered non-target lesions after treatment) and hormone ablation - Uncontrolled or life-threatening symptomatic concomitant disease, including known symptomatic HIV positive with an AIDS defining opportunistic infection within the last year, known symptomatic active hepatitis B or C, or known active tuberculosis - Has undergone a major surgery within 3 weeks prior to starting study treatment or has inadequate healing or recovery from complications of surgery prior to starting study treatment - Has received prior radiotherapy within 2 weeks prior to starting study treatment - Has or had a potentially life-threatening second malignancy requiring systemic treatment within the last 3 years, or which would impede evaluation of treatment response - Clinically significant cardiovascular disease - Patients on a potent CYP3A inhibitor or CPY3A inducer who cannot be changed to another medication - Has an active infection requiring concurrent systemic antibiotic therapy - A woman of child-bearing potential (WOCBP) who has a positive pregnancy test prior to treatment - Is breastfeeding or expecting to conceive or father children within the projected duration of the study

Study Design


Intervention

Drug:
AGX101
Antibody Drug Conjugate

Locations

Country Name City State
United States Sarah Cannon Research Center Nashville Tennessee
United States NEXT Oncology San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
Angiex, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acceptable maximum tolerated dose for participants Maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of AGX101 will be characterized 21 days following the first dose of AGX101 (Day 1 through Day 21)
Primary Number of participants with adverse events Evaluation of the incidence, severity, and duration of adverse events Screening through end of treatment, approximately 6 months and up to 3 years
Secondary Terminal elimination half life (PK) Determination of the terminal elimination half-life (t½) 22 days following the first dose of AGX101 (Day 1 through Day 22)
Secondary AUC (PK) Determination of the AUC in 1 dosing interval 22 days following the first dose of AGX101 (Day 1 through Day 22)
Secondary Cmax (PK) Determination of the Cmax concentration over a dosing interval, systemic clearance, volume of distribution at steady-state (Vss), and accumulation ratio from first dose to steady-state 22 days following the first dose of AGX101 (Day 1 through Day 22)
Secondary Number of Participants with Antidrug Antibodies (ADA) to AGX101 Incidence and titers of ADA will be measured Approximately 6 months and up to 3 years
Secondary Efficacy as measured by Proportion of Participants with Objective Response Rate (ORR) According to RECIST v1.1 Evaluated by the Investigator Determination the objective response rate (ORR) Approximately 6 months and up to 3 years
Secondary Efficacy as measured by Duration of Response (DoR) Assessed by Investigator Determination of the duration of response (DoR) Approximately 6 months and up to 3 years
Secondary Efficacy as measured by Disease Control Rate (DCR) Determination of the disease control rate (DCR) Approximately 6 months and up to 3 years
Secondary Efficacy as measured by Proportion of Participants with Progression Free Survival (PFS) According to RECIST v1.1 Evaluated by the Investigator Determine progression-free survival (PFS)/PFS assessed per immune-related response evaluation criteria (iPFS). Approximately 6 months and up to 3 years
Secondary Efficacy as measured by Duration of Treatment Approximately 6 months and up to 3 years
Secondary Overall Survival Approximately 6 months and up to 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients